Entrada picks Syntimmune vet Mario Saltarello as CMO; Gene therapy maker Orchard hires Ran Zheng as CTO
→ Entrada Therapeutics, the startup launched by 5AM and MPM Capital to develop therapies based on a family of cell-penetrating small cyclic peptides that Ohio State professor Dehua Pei discovered, has found a chief medical officer in Mario Saltarelli. “His experiences at both venture-backed biotechnology and global pharmaceutical companies have involved him in every aspect of bringing a medicine from bench to bedside,” said CEO Dipal Doshi, referring to Saltarelli’s stints at Syntimmune, Vertex, Annexon and Mallinckrodt, among others.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.